Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Dyne wins new Outperform at BMO on prospects for lead drug
Dyne Therapeutics (NASDAQ:DYN) traded higher in the premarket on Wednesday after BMO Capital Markets launched its coverage with an Outperform recommendation and a $50 per share target, citing the ...
Dyne Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...
Charity Today4d
Running for a Cure: Half Marathon Challenge for Muscular Dystrophy
He is running in support of several members of his family who live with myotonic dystrophy type 1, a rare genetic condition that causes progressive muscle ...
Le Lézard5d
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...
KMA Radio5d
Russ Wilson, 61, Adair
Age:61 From:Adair, Iowa Previous: Day and Date:Saturday, March 15, 2025 Time:12:30pm-2:00pm Location:Adair Fire Hall Visitation Location: Visitation Day and Date: Visitation Start: Visitation ...
Researchers identify link to kidney in myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...
Le Lézard6d
Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will present ...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...
News-Medical.Net6d
Research links kidney dysfunction to muscle weakness in myotonic dystrophy type 1
Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature Communications, "Analysis of human urinary extracellular ...
WAGM-TV8d
20-year-old with genetic disorder dies during final family road trip
NEW BRIGHTON, Minn. (WCCO) – A 20-year-old Minnesota man died while embarking on a family trip as part of his final wish. His family spoke about his lasting legacy. Twenty-year-old Giacomo Naylor gave ...